The U.S. Food and Drug Administration approved Merck’s Dificid (fidaxomicin) for a new oral suspension as well as for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in children ages 6 months and older.

With an increased need for the development of vaccines for various illnesses, Pfizer responded with the launch of the company’s Vaccines Division’s Centers of Excellence Network.

The Chinese government is turning to a drug developed by AbbVie for HIV patients as a potential treatment for the coronavirus outbreak that has reached the shores of the United States.

Ipsen decided to temporarily pause dosing in the company’s palovarotene extension studies for patients with fibrodysplasia ossificans progressiva following a recommendation from an Independent Data Monitoring Committee.

John Kapoor, the founder and former chief executive officer of Insys Therapeutics, was sentenced to more than five years in federal prison for the role his company played in the opioid epidemic.

Roche company Genentech announced that the Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy did not hit the primary endpoint in muscle-invasive urothelial cancer (MIUC).